Strongly decreased risk of genital warts after vaccination against human papillomavirus: Nationwide follow-up of vaccinated and unvaccinated girls in Denmark

Clinical Infectious Diseases

Volumn 57, Issue 7, 2013, Pages 929-934

  Blomberg, Maria ^a   Dehlendorff, Christian ^a   Munk, Christian ^a   Kjaer, Susanne K ^a,b  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Condyloma acuminata; Epidemiology; Genital warts; Human papillomavirus; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; CONDYLOMA ACUMINATUM; DENMARK; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NONHUMAN; PRECANCER; PRIORITY JOURNAL; RISK REDUCTION; VACCINATION; WART VIRUS;

CONDYLOMA ACUMINATA; EPIDEMIOLOGY; GENITAL WARTS; HUMAN PAPILLOMAVIRUS; VACCINATION;

ADOLESCENT; CHILD; CONDYLOMATA ACUMINATA; DENMARK; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MASS VACCINATION; PAPILLOMAVIRUS VACCINES; PROPORTIONAL HAZARDS MODELS; RISK; YOUNG ADULT;

EID: 84884406591     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit436     Document Type: Article

References (16)

1. Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med 2011; 53(suppl 1):S12-21.
2. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121:621-32.
3. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 341:c3493.
4. Statens Serum Institut. Childhood Vaccination Programme. Available at: http://www.ssi.dk/English/HealthdataandICT/The%20Danish%20Childhood %20Vaccination%20Programme.aspx. Accessed 9 July 2013.
5. Statens Serum Institut. EPI-NEWS HPV-vaccination - coverage 2012. Available at: http://www.ssi.dk/English/News/EPI-NEWS/2013/No% 2020%20-%202013.aspx. Accessed 9 July 2013.
6. Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2012; 40:130-5.
7. Leval A, Herweijer E, Arnheim-Dahlstrom L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012; 206:860-6.
8. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85:499-502.
9. Mikolajczyk RT, Kraut A, Horn J, Schulze-Rath R, Garbe E. The incidence of anogenital warts in Germany after introduction of HPV vaccination. Eurogin: European Research Organisation on Genital Infection and Neoplasia, Prague, 8-11 July 2012. Abstract SS12-3. Available at: http://www.eurogin.com/2012/images/ pdf/eurogin-2012-abstracts.pdf. Accessed 6 February 2013.
10. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: http://www.R-project.org. Accessed 6 February 2013.
11. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87:544-7.
12. Markowitz L. HPV vaccine - update. 2012. Advisory committee on Immunization Practices (ACIP) meeting, Atlanta, Georgia, 20-1 June 2012. Available at: http://www.cdc.gov/vaccines/recs/acip/slides-jun12. htm. Accessed 9 July 2013.
13. Raymakers AJ, Sadatsafavi M, Marra F, Marra CA. Economic and humanistic burden of external genital warts. Pharmacoeconomics 2012; 30:1-16.
14. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005; 191:731-8.
15. Lacey CJ. Therapy for genital human papillomavirus-related disease. J Clin Virol 2005; 32(suppl 1):S82-90.
16. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30(suppl 5): F123-38.